Shots:

• Hanmi to receive $10M up front- $860M as development- regulatory approval- and commercialization of efinopegdutide along with royalties on sales of the approved product
• Merck to receive an exclusive license to develop- manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea
• Efinopegdutide is a GLP-1/glucagon receptor dual agonist- activating the both the GLP-1 and glucagon receptors- currently being evaluated in multiple P-I & P-II studies- including for the treatment of severely obese individuals with/without T2D

­ Ref: Merck & Co. | Image: Merck